Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 28.
doi: 10.1002/ijc.70214. Online ahead of print.

Efficacy of adjuvant immunotherapy and immunochemotherapy in esophageal squamous cell carcinoma: A retrospective cohort study

Kai-Yuan Jiang  1   2 , Wen-Long Hu  3 , Shi-Xiang Liu  1 , Lei Wang  1 , Jie Li  1 , Lin Lin  1 , Heng-Tao Lin  4 , Jun-Jie Wang  5 , Long-Qi Chen  1 , Dong Tian  1
Affiliations

Efficacy of adjuvant immunotherapy and immunochemotherapy in esophageal squamous cell carcinoma: A retrospective cohort study

Kai-Yuan Jiang et al. Int J Cancer. .

Abstract

There remains uncertainty regarding the efficacy of adjuvant immunotherapy following neoadjuvant therapy and surgery in patients with esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the prognostic value of adjuvant immunotherapy and immunochemotherapy (ICT) for ESCC patients. This retrospective cohort study reviewed ESCC patients who underwent neoadjuvant therapy followed by radical esophagectomy. Postoperative adjuvant therapy included chemotherapy, chemoradiotherapy (CRT), immunotherapy, and ICT. Overall survival (OS) and disease-free survival (DFS) were compared using the Kaplan-Meier method, and independent prognostic factors were identified via multivariate Cox regression analysis. A total of 690 patients were included, of whom 176 (25.5%) received adjuvant therapy, with 61, 37, 45, and 33 patients receiving chemotherapy, CRT, immunotherapy, and ICT, respectively. Among the adjuvant therapy group, both immunotherapy and ICT significantly improved OS compared to CRT (p < .001 and p = .011, respectively). For DFS, the immunotherapy group showed significantly better survival than the chemotherapy and CRT groups (p = .042 and p < .001, respectively). Multivariate analysis identified immunotherapy and ICT as independent favorable prognostic factors for both OS and DFS (all p < .05). Furthermore, patients receiving perioperative immunotherapy achieved superior OS and DFS than those receiving other treatment regimens (all p < .05). Our findings suggest potential benefits of immunotherapy and ICT as adjuvant therapy for ESCC. It also indicates that perioperative immunotherapy may have broader applicability beyond current recommendations and could contribute to optimizing treatment strategies.

Keywords: adjuvant therapy; esophageal squamous cell carcinoma; immunochemotherapy; immunotherapy; prognosis.

PubMed Disclaimer

References

REFERENCES

    1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229‐263. doi:10.3322/caac.21834
    1. Yang J, Liu X, Cao S, Dong X, Rao S, Cai K. Understanding esophageal cancer: the challenges and opportunities for the next decade. Front Oncol. 2020;10:1727. doi:10.3389/fonc.2020.01727
    1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134:783‐791. doi:10.1097/cm9.0000000000001474
    1. Demarest CT, Chang AC. The landmark series: multimodal therapy for esophageal cancer. Ann Surg Oncol. 2021;28:3375‐3382. doi:10.1245/s10434‐020‐09565‐5
    1. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION‐3): a multicentre, randomised, open‐label, phase 3 trial. Lancet Oncol. 2019;20:1506‐1517.

LinkOut - more resources